CVRx, Inc.

NASDAQ:CVRX

Medical - Devices

Healthcare
$2.63 +2.28%

+$0.11 today

Market cap
$69.79M
Beta
0.77
P/E (TTM)
-2.5
EPS (TTM)
-$2.00
52W Low $4.37High $11.30

Volume 0.37M

Average 0.30M

CVRX EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

CVRx, Inc.NASDAQ: CVRX

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$11.36M, compared with -$12.13M a year earlier. Trailing-twelve-month EBITDA was -$45.97M.

Context

  • EBITDA amounted to 82.5% of revenue in FY2025, down 24.5 pp from a year earlier.
  • EBITDA grew in size in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 5 analysts of -$48.49M (-3.7%) for the fiscal year ending Dec 2026, a slowdown from the +14.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$11.36M-9.9% QoQ
Last fiscal yearDec 2025
-$46.74M+14.9% YoY
LTMMar 2026
-$45.97M-0.0% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6.3%+8.8%+2.5 pp
1 year+14.9%-3.7%-18.6 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(46.74M) USD
Year-over-year change
+14.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How CVRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -0.0% is the 6th highest of 10, against a peer median of +5.3%.
  • EBITDA amounts to 77.8% of revenue for CVRX, versus a peer median of 51.1%.
CVRX Competitors
EBITDA for CVRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VMDViemed Healthcare, Inc.LTM Mar 2026$53.03M USD+28.1%+27.6%18.5%
SNWVSANUWAVE Health, Inc.LTM Mar 2026$22.67M USD+217.1%+59.4%51.1%
CERSCerus CorporationLTM Mar 2026$1.19M USD+114.0%—0.5%
MASS908 Devices Inc.LTM Mar 2026-$26.57M USD+5.3%—46.0%
SGHTSight Sciences, Inc.LTM Mar 2026-$31.68M USD+27.7%—39.8%
PRQRProQR Therapeutics N.V.LTM Mar 2026-€42.88M EUR-67.7%—319.0%
CVRXCVRx, Inc.LTM Mar 2026-$45.97M USD-0.0%—77.8%
NNOXNano-X Imaging Ltd.LTM Dec 2025-$49M USD-11.0%—376.3%
SENSSenseonics Holdings, Inc.LTM Mar 2026-$80.8M USD-25.3%—198.5%
QTRXQuanterix CorporationLTM Mar 2026-$84.67M USD-104.0%—58.4%
Peer median (excluding CVRX) —+5.3%+43.5%51.1%

Competitors are the stored peer set for CVRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue13.04M22.47M39.3M51.29M56.65M
Cost of Revenue3.64M5M6.26M8.33M8.31M
Gross Profit9.4M17.47M33.04M42.96M48.34M
Gross Margin72.1%77.8%84.1%83.8%85.3%
Research & Development7.5M9.95M11.63M11.13M11.13M
Selling, General & Admin27.86M50.05M64.51M91.32M88.47M
Operating Expenses35.36M60M76.14M102.45M99.61M
Depreciation & Amortization168K412K522K619K756K
EBITDA(40.6M)(40.74M)(38.73M)(54.89M)(46.74M)
EBITDA Margin-311.4%-181.3%-98.6%-107.0%-82.5%
Operating Income(25.97M)(42.53M)(43.1M)(59.49M)(51.27M)
Operating Margin-199.2%-189.3%-109.7%-116.0%-90.5%
Interest Income00000
Interest Expense2.22M165K1.8M4.4M5.83M
Other Income / Expenses(17.02M)1.21M2.05M(420K)(2.06M)
Income Before Tax(42.99M)(41.32M)(41.05M)(59.91M)(53.32M)
Pre-Tax Margin-329.8%-183.9%-104.5%-116.8%-94.1%
Income Tax Expense91K109K147K55K(18K)
Net Income(43.08M)(41.43M)(41.2M)(59.97M)(53.31M)
Net Margin-330.5%-184.4%-104.8%-116.9%-94.1%
EPS (Basic)(2.11)(2.02)(1.99)(2.65)(2.04)
EPS (Diluted)(2.11)(2.02)(1.99)(2.65)(2.04)
Weighted Avg Shares20.72M20.51M20.7M22.6M26.08M
Weighted Avg Shares (Diluted)20.72M20.53M20.75M22.6M26.08M

CVRx, Inc.

NASDAQ:CVRX

Intrinsic Alpha fair value

Locked

Current Price

$2.63

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.